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Summary
Artemisinin- and artesunate-resistant Plasmodium
chabaudi mutants, AS-ART and AS-ATN, were previ-
ously selected from chloroquine-resistant clones
AS-30CQ and AS-15CQ respectively. Now, a genetic
cross between AS-ART and the artemisinin-sensitive
clone AJ has been analysed by Linkage Group
Selection. A genetic linkage group on chromosome 2
was selected under artemisinin treatment. Within this
locus, we identiﬁed two different mutations in a gene
encoding a deubiquitinating enzyme. A distinct muta-
tion occurred in each of the clones AS-30CQ and
AS-ATN, relative to their respective progenitors in the
AS lineage. The mutations occurred independently in
different clones under drug selection with chloro-
quine (high concentration) or artesunate. Each muta-
tion maps to a critical residue in a homologous
human deubiquitinating protein structure. Although
one mutation could theoretically account for the
resistance of AS-ATN to artemisinin derivates, the
other cannot account solely for the resistance of
AS-ART, relative to the responses of its sensitive pro-
genitor AS-30CQ. Two lines of Plasmodium falci-
parum with decreased susceptibility to artemisinin
were also selected. Their drug-response phenotype
was not genetically stable. No mutations in the UBP-1
gene encoding the P. falciparum orthologue of the
deubiquitinating enzyme were observed. The pos-
sible signiﬁcance of these mutations in parasite
responses to chloroquine or artemisinin is discussed.
Introduction
Malaria is estimated to cause the death of over one million
people annually, mainly children in Africa. Moreover,
despite intensive research, the overall disease burden
arising from infections by the malaria parasite Plasmo-
dium falciparum is increasing. One major factor has been
the emergence and spread of malaria parasites which are
resistant to antimalarial drugs such as chloroquine or
pyrimethamine/sulphadoxine. Consequently, many coun-
tries have now introduced artemisinin (ART) derivatives
as their ﬁrst-line therapy, in combination with other
drugs (such as meﬂoquine, amodiaquine, piperaquine,
pyrimethamine/sulphadoxine or lumefantrine) (World
Health Organization, 2006). These artemisinin combina-
tion therapies (ACTs) present favourable pharmacokinet-
ics and are thought to reduce the probability of mutations
that underlie resistance and treatment failure emerging in
parasite populations (White, 1999). Artemisinin has a
short half-life but acts extremely quickly in reducing para-
site densities and symptoms. The activation, mechanisms
of action and targets of artemisinin derivatives have been
vigorously investigated and debated (Olliaro et al., 2001;
Meshnick, 2002; Krishna et al., 2006). For instance, the
activation of the endoperoxide group might produce a
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Journal compilation © 2007 Blackwell Publishing Ltdcarbon-centred radical either after activation by Fe(II) in
reduced haem (Meshnick et al., 1991) or as a result of
interactions with iron-sulphur proteins in the mitochondrial
electron-transport chain (Li et al., 2005). Candidate
targets have included haem itself (Robert et al., 2005) and
the SERCA-type Ca2+-ATPase (Eckstein-Ludwig et al.,
2003). There is also debate regarding the extent to which
chloroquine or artemisinin derivatives aggravate the oxi-
dative stress normally incurred by parasites, for example
during haemoglobin digestion and subsequent haem pro-
cessing (oxidation of Fe2+-protoporphyrin IX to Fe3+-
protoporphyrin IX in the food vacuole, with a concomitant
release of reactive oxygen species) (reviewed in Tilley
et al., 2001; Becker et al., 2004).
Afonso et al. (2006) recently reported the selection of
two artemisinin-resistant mutant clones, AS-ART and
AS-ATN (Fig. 1) in the rodent malaria parasite Plasmo-
dium chabaudi. They were derived from chloroquine-
resistant clones by serial passage in the presence of
increasing but subcurative doses of artemisinin or artesu-
nate (ATN) respectively. After cloning, both showed
improved growth in the presence of either ART or ATN,
relative to their sensitive progenitors, AS-30CQ and
AS-15CQ. Minimum curative doses of artemisinin
increased 15-fold in AS-ART and 26-fold in AS-ATN (rela-
tive to their sensitive progenitors) while those of artesu-
nate increased ﬁve- to sixfold in both clones. These lines
exhibited stable drug response phenotypes after cloning,
passage in untreated mice and transmission through the
mosquito vector.
What resistance mechanisms are possible and what are
their genetic bases? Initial sequence analysis of these
clones (and their sensitive progenitors) began with genes
for which published evidence suggests a potential involve-
ment in modulating parasite responses to artemisinin
derivatives. These genes were the P. chabaudi ortho-
logues of pfatp6, encoding the SERCA-type Ca2+-ATPase
(Eckstein-Ludwig et al., 2003; Jambou et al., 2005; Uhle-
mann et al., 2005), pfcrt (Sidhu et al., 2002), pfmdr1 (Reed
et al., 2000; Ferrer-Rodríguez et al., 2004; Price et al.,
2004; Sidhu et al., 2005) and pftctp (encoding translation-
ally controlled tumour protein,TCTP) (Bhisutthibhan et al.,
1998; Walker et al., 2000). Sequencing of AS-ART and
AS-ATN and their progenitors (AS-30CQ and AS-15CQ)
showed that there were no mutations or copy number
changes in these genes (Afonso et al., 2006).
Plasmodium chabaudi is a robust model system for
identifying genetic loci, candidate genes and individual
mutations underlying drug resistance (Carlton et al.,
2001). Classical genetic studies such as traditional
linkage analysis (Carlton et al., 1998; Hayton et al., 2002;
Cravo et al., 2003; Hunt et al., 2004a,b) or Linkage Group
Selection (LGS) (Culleton et al., 2005), both of which
analyse linkage between genotype and phenotype (Carter
et al., 2007), have been employed to this end. LGS, used
in this current investigation, characterizes the uncloned
progeny of a genetic cross (between a resistant and sen-
sitive parasite) by measuring the proportion of parental
polymorphic markers at genome-wide loci, before and
after drug treatment. Markers from the sensitive parent
that are linked to the gene underlying the resistance phe-
notype are reduced in proportion or intensity after drug
treatment, forming a ‘selection valley’. We have previously
used ampliﬁed fragment length polymorphisms (AFLP)
that distinguish the two parental lines in the genetic cross
(Culleton et al., 2005; Martinelli et al., 2005a). A genetic
linkage map (Martinelli et al., 2005b), a genome
sequence database and a complete syntenic map (Kooij
et al., 2006) allow us to map genes and markers geneti-
cally and physically, thus allowing identiﬁcation of loci
AS
AS-pyr1*
AS-3CQ*
AS-15CQ
AS-30CQ*
Pyr resistant, CQ sensitive
CQ resistant (low)
CQ resistant (intermediate)
CQ resistant (high)
AS-ATN*
AS-ART*
V739F
V770F
No mutation
Fig. 1. Drug-resistant mutants – the AS lineage. Mutants of P. chabaudi cloned isolate AS have been selected by passage in the presence of
pyrimethamine, low, intermediate and high chloroquine concentrations, artesunate and artemisinin, to give lines and clones AS-Pyr (Walliker
et al., 1975), AS-3CQ (Rosario, 1976; Carlton et al., 1998), AS-15CQ and AS-30CQ (Padua, 1981), AS-ATN and AS-ART (Afonso et al., 2006)
respectively. An asterisk denotes that these clones have been used to generate genetic crosses with the cloned isolate, AJ. The genetic cross
investigated in this study used AS-ART and AJ as parental clones. The mutations shown, V739F and V770F, refer to those in UBP-1,
described in this study.
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locus can be identiﬁed by comparative sequencing of
genes from both the resistant mutant and its sensitive
progenitor.
Here we describe the analysis of a genetic cross
between AS-ART and AJ and the identiﬁcation of a selec-
tion valley on P. chabaudi chromosome 2 detected by
LGS analysis after artemisinin treatment. Subsequently
we have identiﬁed two independent non-synonymous
mutations in a gene encoding a deubiquitinating enzyme
within this locus. One mutation appears in AS-ATN
derived from AS-15CQ after artesunate selection and the
other inAS-30CQ (also derived fromAS-15CQ) after chlo-
roquine selection.
Results
Genetic crosses and LGS
We performed three independent genetic crosses
between the artemisinin-resistant clone, AS-ART (Afonso
et al., 2006) and the genetically distinct sensitive parasite
clone AJ. Uncloned progeny from these crosses were
pooled in equal proportions and passaged through two
groups of mice. One group was treated with 25 mg
artemisinin/kg/day for ﬁve consecutive days [day 0 to day
4 post infection (pi)]. The other group was untreated.
Parasites were harvested on days 10 pi and 8 pi, respec-
tively, and DNA samples from these groups were analy-
sed by AFLP. The comparative intensities (CIs) for AFLP
bands speciﬁc to the sensitive parent AJ, and their loca-
tion within the P. chabaudi genetic linkage map are shown
in Fig. 2.
Seven highly linked AFLP markers (mapping to chro-
mosome 2) showed the lowest CIs. CIs of other AFLPs in
three other linkage groups (mapping to chromosomes 1, 8
and 14) also appeared to be lower than those shown
across the genome as a whole, suggesting possible
selection or experimental variation at these loci.
Mapping of AFLP markers
All of the AFLP bands showing reduced CIs had previ-
ously been placed on a genetic linkage map (Martinelli
et al., 2005b). We conﬁrmed the physical location of these
AFLP markers (see Experimental procedures). The data
for a number of AFLP markers in the four linkage groups
under possible selection are shown in Table 1. Markers
AJGA01TA,AJAC01TG andAJAC03TAall mapped to loci
on P. falciparum chromosome 6 that are syntenic to
P. chabaudi chromosome 1. AJGA01CA, AJAC02AA,
AJGA02CA and AJGA01TT mapped to P. falciparum
chromosome 1 or 7 at loci syntenic to P. chabaudi chro-
mosome 2. AJAC03AT and AJAT01TA mapped to loci on
P. falciparum chromosome 9 that are syntenic to
P. chabaudi chromosome 8. Finally, AJAG02AT,
AJAC05AT and AJAA01TA mapped to P. falciparum chro-
mosome 13 or 12 at loci that are syntenic with P. chabaudi
chromosome 14 (Table 1). Other markers were not
mapped, either because of poor sequence quality or
because marker sequence did not identify a P. chabaudi
contig unambiguously.
Plasmodium chabaudi chromosome 2 is syntenic with
two blocks of the P. falciparum genome, one each on
chromosomes 1 and 7 (Kooij et al., 2006) (Fig. 3). These
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Fig. 2. LGS – artemisin treatment of AS-ART ¥ AJ genetic cross. The selection on a set of AJ-speciﬁc genome-wide AFLP markers (Grech
et al., 2002) in the ‘treated’ group relative to the ‘untreated’ group is represented by Comparative Intensity (Martinelli et al., 2004) (logarithmic
scale) of AFLP markers (vertical axis) and their position (revised, see Table 1) in a genetic linkage map (horizontal axis), assigned to speciﬁc
chromosomes. AFLP markers mapped by sequence analysis (Fig. 3) are indicated.
Deubiquitination mutations and drug-resistant malaria 29
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Molecular Microbiology, 65, 27–40T
a
b
l
e
1
.
P
h
y
s
i
c
a
l
a
n
d
G
e
n
e
t
i
c
m
a
p
p
i
n
g
o
f
A
F
L
P
m
a
r
k
e
r
s
w
i
t
h
l
o
w
C
I
.
A
F
L
P
m
a
r
k
e
r
C
o
m
p
a
r
a
t
i
v
e
i
n
t
e
n
s
i
t
y
P
.
c
h
a
b
a
u
d
i
l
i
n
k
a
g
e
g
r
o
u
p
a
c
c
o
r
d
i
n
g
t
o
M
a
r
t
i
n
e
l
l
i
e
t
a
l
.
(
2
0
0
5
b
)
C
o
n
t
i
g
I
D
L
e
n
g
t
h
o
f
c
o
n
t
i
g
(
n
t
)
A
p
p
r
o
x
i
m
a
t
e
p
o
s
i
t
i
o
n
o
f
A
F
L
P
o
n
c
o
n
t
i
g
N
e
a
r
e
s
t
g
e
n
e
P
.
f
a
l
c
i
p
a
r
u
m
g
e
n
o
m
i
c
l
o
c
u
s
P
.
c
h
a
b
a
u
d
i
c
h
r
o
m
o
s
o
m
e
a
c
c
o
r
d
i
n
g
t
o
s
y
n
t
e
n
y
K
o
o
i
j
e
t
a
l
.
(
2
0
0
6
)
G
e
n
e
G
e
n
e
a
n
n
o
t
a
t
i
o
n
G
e
n
e
I
D
A
J
G
A
0
1
T
A
0
.
3
2
G
r
o
u
p
3
8
4
5
2
.
1
1
6
1
5
3
6
5
0
8
5
0
P
F
F
0
1
7
5
c
H
y
p
o
t
h
e
t
i
c
a
l
3
8
8
5
7
8
8
p
f
0
6
–
0
1
4
4
1
A
J
A
C
0
1
T
G
0
.
4
5
G
r
o
u
p
3
8
4
5
2
.
1
1
6
1
5
3
6
3
6
9
0
0
P
F
F
0
1
8
5
c
H
y
p
o
t
h
e
t
i
c
a
l
3
8
8
5
7
9
0
p
f
0
6
–
0
1
6
0
1
A
J
A
C
0
3
T
A
0
.
4
8
G
r
o
u
p
3
8
1
2
9
0
9
5
3
9
8
9
2
5
0
0
P
F
F
0
4
8
0
w
H
y
p
o
t
h
e
t
i
c
a
l
3
8
8
5
8
7
7
p
f
0
6
–
0
4
1
9
1
A
J
G
A
0
1
C
A
0
.
2
0
C
h
r
1
0
4
6
2
6
0
4
8
4
5
9
4
0
0
M
A
L
1
P
1
.
7
1
H
y
p
o
t
h
e
t
i
c
a
l
8
1
3
1
6
7
p
f
0
1
–
0
1
3
2
2
A
J
A
C
0
2
A
A
0
.
1
7
C
h
r
1
0
4
6
2
6
0
4
8
4
3
4
3
0
0
M
A
L
7
P
1
.
1
4
7
U
b
i
q
u
i
t
i
n
C
-
t
e
r
m
i
n
a
l
h
y
d
r
o
l
a
s
e
2
6
5
5
0
2
3
p
f
0
7
–
1
0
2
9
2
A
J
G
A
0
3
A
G
0
.
2
2
C
h
r
1
0
4
6
2
6
0
4
8
4
3
3
6
5
0
M
A
L
7
P
1
.
1
4
7
U
b
i
q
u
i
t
i
n
C
-
t
e
r
m
i
n
a
l
h
y
d
r
o
l
a
s
e
2
6
5
5
0
2
3
p
f
0
7
–
1
0
3
0
2
A
J
G
A
0
2
C
A
0
.
2
8
C
h
r
1
0
4
6
2
6
0
4
8
4
2
1
7
0
0
P
F
0
7
_
0
1
0
8
H
y
p
o
t
h
e
t
i
c
a
l
2
6
5
5
1
6
1
p
f
0
7
–
1
0
4
5
2
A
J
A
C
0
2
A
C
0
.
3
1
C
h
r
1
0
I
n
s
u
f
f
i
c
i
e
n
t
s
e
q
u
e
n
c
e
f
o
r
a
n
a
l
y
s
i
s
n
a
n
a
A
J
A
G
0
3
A
C
0
.
2
5
C
h
r
1
0
I
n
s
u
f
f
i
c
i
e
n
t
s
e
q
u
e
n
c
e
f
o
r
a
n
a
l
y
s
i
s
n
a
n
a
A
J
G
A
0
1
T
T
0
.
2
7
C
h
r
1
0
4
6
2
6
0
4
8
4
1
2
8
1
0
M
A
L
7
P
1
.
1
4
9
H
y
p
o
t
h
e
t
i
c
a
l
2
6
5
5
0
2
4
p
f
0
7
–
1
0
5
3
2
A
J
A
C
0
3
A
T
0
.
3
2
C
h
r
8
9
3
6
.
0
6
1
9
6
4
1
3
4
0
0
P
F
I
0
4
6
0
w
H
y
p
o
t
h
e
t
i
c
a
l
8
1
3
3
7
2
p
f
0
9
–
0
4
3
1
8
A
J
A
T
0
1
T
A
0
.
3
2
C
h
r
8
1
4
8
9
7
9
0
7
2
1
5
0
P
F
1
5
2
0
w
H
y
p
o
t
h
e
t
i
c
a
l
8
1
3
5
8
4
p
f
0
9
–
1
2
6
1
8
A
J
A
G
0
2
A
T
0
.
3
3
G
r
o
u
p
2
4
0
8
6
3
3
5
3
1
2
0
0
0
P
F
1
3
–
0
0
6
9
T
r
a
n
s
l
a
t
i
o
n
i
n
i
t
i
a
t
i
o
n
f
a
c
t
o
r
-
2
,
p
u
t
a
t
i
v
e
8
1
4
0
4
7
p
f
1
3
–
0
4
8
2
1
4
A
J
A
C
0
5
A
T
0
.
5
0
G
r
o
u
p
2
1
2
1
4
1
1
5
6
3
2
9
5
0
P
F
L
0
6
1
5
w
H
y
p
o
t
h
e
t
i
c
a
l
8
1
1
1
7
6
p
f
1
2
–
0
5
4
9
1
4
A
J
A
A
0
1
T
A
0
.
4
0
G
r
o
u
p
2
8
8
2
6
1
2
2
3
4
9
6
0
0
P
F
L
0
8
0
5
w
H
y
p
o
t
h
e
t
i
c
a
l
8
1
1
2
1
4
p
f
1
2
–
0
6
6
5
1
4
T
h
e
A
J
-
s
p
e
c
i
ﬁ
c
A
F
L
P
b
a
n
d
s
t
h
a
t
s
h
o
w
r
e
d
u
c
e
d
C
I
s
a
r
e
s
h
o
w
n
w
i
t
h
a
p
h
y
s
i
c
a
l
l
o
c
a
t
i
o
n
(
P
.
f
a
l
c
i
p
a
r
u
m
g
e
n
o
m
i
c
l
o
c
u
s
)
o
f
h
o
m
o
l
o
g
o
u
s
p
o
s
i
t
i
o
n
s
i
n
P
.
f
a
l
c
i
p
a
r
u
m
(
p
f
x
x
-
y
y
y
y
d
e
n
o
t
e
s
l
o
c
u
s
y
y
y
y
k
b
a
l
o
n
g
c
h
r
o
m
o
s
o
m
e
x
x
)
.
T
h
i
s
l
o
c
u
s
h
a
s
b
e
e
n
m
a
p
p
e
d
t
o
P
.
c
h
a
b
a
u
d
i
c
h
r
o
m
o
s
o
m
e
s
u
s
i
n
g
d
e
t
a
i
l
e
d
s
y
n
t
e
n
i
c
r
e
l
a
t
i
o
n
s
h
i
p
s
(
K
o
o
i
j
e
t
a
l
.
,
2
0
0
6
)
.
T
h
e
p
r
e
v
i
o
u
s
l
y
r
e
p
o
r
t
e
d
l
i
n
k
a
g
e
g
r
o
u
p
s
(
M
a
r
t
i
n
e
l
l
i
e
t
a
l
.
,
2
0
0
5
b
)
a
r
e
s
h
o
w
n
.
T
h
o
s
e
m
a
r
k
e
r
s
p
r
e
v
i
o
u
s
l
y
a
l
l
o
c
a
t
e
d
t
o
‘
l
i
n
k
a
g
e
g
r
o
u
p
3
8
′
h
a
d
n
o
t
b
e
e
n
r
e
p
o
r
t
e
d
b
y
M
a
r
t
i
n
e
l
l
i
e
t
a
l
.
(
2
0
0
5
b
)
b
e
c
a
u
s
e
i
t
c
o
n
t
a
i
n
e
d
l
e
s
s
t
h
a
n
e
i
g
h
t
m
a
r
k
e
r
s
.
T
h
e
y
h
a
v
e
n
o
w
b
e
e
n
a
s
s
i
g
n
e
d
t
o
P
.
f
a
l
c
i
p
a
r
u
m
c
h
r
o
m
o
s
o
m
e
1
o
n
t
h
e
b
a
s
i
s
o
f
p
h
y
s
i
c
a
l
m
a
p
p
i
n
g
d
e
s
c
r
i
b
e
d
i
n
t
h
e
t
e
x
t
.
S
i
m
i
l
a
r
l
y
,
m
a
r
k
e
r
s
p
r
e
v
i
o
u
s
l
y
a
l
l
o
c
a
t
e
d
t
o
‘
g
r
o
u
p
2
′
h
a
v
e
n
o
w
b
e
e
n
a
s
s
i
g
n
e
d
t
o
c
h
r
o
m
o
s
o
m
e
1
4
.
M
a
r
k
e
r
s
n
o
w
a
s
s
i
g
n
e
d
t
o
c
h
r
o
m
o
s
o
m
e
2
h
a
d
p
r
e
v
i
o
u
s
l
y
b
e
e
n
a
s
s
i
g
n
e
d
(
i
n
c
o
r
r
e
c
t
l
y
)
t
o
c
h
r
o
m
o
s
o
m
e
1
0
.
T
h
i
s
a
s
s
i
g
n
m
e
n
t
w
a
s
b
a
s
e
d
u
p
o
n
p
r
e
s
u
m
e
d
l
i
n
k
a
g
e
o
f
t
h
e
s
e
A
F
L
P
m
a
r
k
e
r
s
t
o
a
p
h
y
s
i
c
a
l
l
y
m
a
p
p
e
d
R
F
L
P
m
a
r
k
e
r
,
v
a
c
u
o
l
a
r
A
T
P
a
s
e
s
u
b
u
n
i
t
B
(
K
a
r
c
z
e
t
a
l
.
,
1
9
9
4
)
,
f
o
r
w
h
i
c
h
t
h
e
i
n
h
e
r
i
t
a
n
c
e
d
a
t
a
w
e
r
e
o
n
l
y
a
v
a
i
l
a
b
l
e
f
o
r
n
i
n
e
(
o
u
t
o
f
2
8
p
o
s
s
i
b
l
e
)
r
e
c
o
m
b
i
n
a
n
t
c
l
o
n
e
s
(
C
a
r
l
t
o
n
e
t
a
l
.
,
1
9
9
8
)
.
H
o
w
e
v
e
r
,
t
h
e
i
n
h
e
r
i
t
a
n
c
e
d
a
t
a
f
o
r
a
n
o
t
h
e
r
R
F
L
P
m
a
r
k
e
r
,
C
a
2
+
-
d
e
p
e
n
d
e
n
t
A
T
P
a
s
e
(
M
u
r
a
k
a
m
i
e
t
a
l
.
,
1
9
9
0
)
,
a
s
s
i
g
n
e
d
b
y
P
F
G
E
a
n
a
l
y
s
i
s
t
o
c
h
r
o
m
o
s
o
m
e
2
,
w
e
r
e
a
l
s
o
o
n
l
y
a
v
a
i
l
a
b
l
e
f
o
r
n
i
n
e
(
o
u
t
o
f
2
8
p
o
s
s
i
b
l
e
)
c
l
o
n
e
s
(
C
a
r
l
t
o
n
e
t
a
l
.
,
1
9
9
8
)
.
I
n
s
p
e
c
t
i
o
n
o
f
d
a
t
a
s
h
o
w
e
d
t
h
a
t
t
h
e
g
r
o
u
p
o
f
A
F
L
P
m
a
r
k
e
r
s
,
f
o
r
m
e
r
l
y
a
s
s
i
g
n
e
d
t
o
c
h
r
o
m
o
s
o
m
e
1
0
c
o
u
l
d
a
l
s
o
b
e
l
i
n
k
e
d
t
o
t
h
e
C
a
2
+
-
d
e
p
e
n
d
e
n
t
A
T
P
a
s
e
.
A
l
t
h
o
u
g
h
t
h
i
s
m
a
y
b
e
c
o
n
ﬁ
r
m
e
d
b
y
c
h
a
r
a
c
t
e
r
i
z
a
t
i
o
n
o
f
t
h
e
i
n
h
e
r
i
t
a
n
c
e
p
a
t
t
e
r
n
s
o
f
R
F
L
P
s
C
a
2
+
-
d
e
p
e
n
d
e
n
t
A
T
P
a
s
e
a
n
d
v
a
c
u
o
l
a
r
A
T
P
a
s
e
,
s
u
b
u
n
i
t
B
,
t
h
e
d
a
t
a
p
r
e
s
e
n
t
e
d
h
e
r
e
d
e
m
o
n
s
t
r
a
t
e
s
p
h
y
s
i
c
a
l
l
i
n
k
i
n
g
o
f
t
h
e
A
F
L
P
m
a
r
k
e
r
s
t
o
c
h
r
o
m
o
s
o
m
e
2
.
30 P. Hunt et al.
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Molecular Microbiology, 65, 27–40regions deﬁne approximately 551 kb of syntenic sequence
in P. falciparum, encoding approximately 130 genes.
Conﬁrmation of selection by quantitative SNP analysis
(pyrosequencing)
We wished to conﬁrm independently the proportions of AJ
alleles of genes in parasite populations after artemisinin
treatment. We therefore measured proportions of AS and
AJ SNPs at 93 loci distributed evenly across the genome,
using pyrosequencing (Cheesman et al., 2007) which can
measure the proportions of SNPs in a mixed population
with greater precision and accuracy than proportional
AFLP. The data (Fig. 4) show that the proportions of
genome-wide AJ alleles after artemisinin treatment are
generally reduced (relative to the untreated group) as
expected, probably because of the loss of parental drug-
sensitive AJ parasites during drug treatment. However,
there were particularly large and consistent reductions at
loci on chromosome 2 and, to a lesser extent, at loci on
chromosomes 1, 8 and 14, giving further evidence of
selection at these loci. Using pyrosequencing, we also
estimated SNP proportions at loci on chromosomes 2, 8
and 14 in DNAderived from the three independent crosses
between AS-ART and AJ. We observed reduced AJ
proportions on chromosomes 2, 8 and 14, while loci on
chromosome 6 (control) showed no selection in artem-
isinin-selected populations (Supplementary material).
Identiﬁcation of ubp-1 mutation on P. chabaudi
chromosome 2
Within P. chabaudi chromosome 2, we sequenced a
number of genes (Fig. 3) from AS-ART and AS-ATN to
search for mutations that might account for selection of
this locus during LGS. One gene, the orthologue of
P. falciparum MAL1P1.34b, encodes a putative deubiq-
uitinating protease (DUB), here termed ubiquitin-speciﬁc
protease-1 (UBP-1). Within this gene, we identiﬁed two
G to T mutations that are predicted to generate two non-
synonymous substitutions in AS-ATN and AS-30CQ,
respectively, namely V739F and V770F (Fig. 1).
However, there was no mutation in AS-ART relative to
AS-30CQ. Mutations that underlie the resistance of
AS-ART to artemisinin (and presumably, artesunate),
relative to those of AS-30CQ have therefore not been
identiﬁed because the V770F mutation was already
present in the AS-30CQ clone before ART selection. In
order to evaluate the signiﬁcance of the two mutations in
the P. chabaudi homologue of MAL1P1.34b, especially
regarding their possible role in P. falciparum, we aligned
the predicted amino-acid sequences of the orthologous
P. falciparum and the P. chabaudi proteins (Fig. 5).
Extensive identity between the two sequences occurs
close to the N-terminus and in a larger section in the
C-terminus of the proteins. Both mutations map to the
highly conserved C-terminal part of this DUB, suggesting
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Fig. 3. P. chabaudi chromosome 2 map – markers, genes and synteny. P. chabaudi chromosome 2 (blue + green bar; double-headed arrow,
top) and its syntenic blocks relative to P. falciparum chromosome 1 (blue) and 7 (green) (double-headed arrows, bottom) are shown. The
genes at the extremities of these blocks are shown with their chromosomal loci (pfxx-yyyy, where xx is the chromosome and yyyy the position
in kb, yellow). Note that the syntenic block from P. falciparum chromosome 1 is reversed in direction. The position of AFLPs that were
physically mapped (BLAST) and homologous positions in P. falciparum are shown (pink). Genes (not mutated) sequenced during current study
are shown (purple). Mutated gene (UBP-1) is shown (red). The scale (100 kb intervals) indicates distances in P. falciparum. The positions of
SNP allele quantiﬁcation assays (pyrosequencing) are shown (green circles); these are, left to right, pf01–0406, pf01–0399, pf01–0323,
pf01–0265, pf01–0197, pf01–0150, pf01–0129, pf07–1006 and pf07–1151.
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parts of the enzyme.
Because AS-ART markers on chromosome 2 appear to
be positively selected by artemisinin treatment, we also
sequenced, from AS-ART, another DUB homologue
(orthologous to MAL71P.147) which also lies on the pre-
dicted locus of P. chabaudi chromosome 2 (Fig. 3). No
mutation was identiﬁed in this gene (termed here as
ubp-2) in the AS-ART clone. In order to discount the
possibility that ubp-1 mutations arose by chance during a
burst of mutation activity around this locus (genomic
region), we sequenced four other genes nearby, namely
the P. chabaudi orthologues of MAL1.P1.35, MAL1P1.36,
MAL1P1.40 and MAL1P1.52. None of these showed
mutations in their predicted coding sequences or devia-
tion from the P. chabaudi AS genome database entries.
Mapping UBP-1 mutations in a crystal structure
We used the highly conserved predicted C-terminal
P. chabaudi amino acid sequence (aa 595–963) of
UBP-1 to interrogate a protein structure database by
BLAST search. We identiﬁed the core domain of a human
homologue (herpes virus-associated ubiquitin-speciﬁc
protease, HAUSP), for which the crystal structure has
been solved (Hu et al., 2002). The alignment between
the P. chabaudi UBP-1 and the HAUSP predicted protein
sequences is shown (Fig. 6). Twenty-eight per cent of
the P. chabaudi UBP-1 amino acids are identical to
those of HAUSP, 23% are conservative substitutions and
49% are not conserved. We investigated whether those
residues identiﬁed as having important structural roles
(e.g. catalytic involvement, binding of ubiquitin) were
particularly conserved between the two proteins. Out of
35 residues identiﬁed as having such roles (Hu et al.,
2002) 25 (72%) were identical in the P. chabaudi UBP-1
sequence, ﬁve (14%) were conservative substitutions
and only ﬁve (14%) residues showed non-conservative
substitutions (Fig. 6). We therefore concluded that these
homologues are likely to share many structural and
functional similarities. The V739F mutation (equivalent to
HAUSP V296) maps to an end of alpha helix 5 close
to the proposed catalytic cysteine, C628 (equivalent to
HAUSP C223). The other mutation, V770F (equivalent to
HAUSP I332), maps to a hydrophobic pocket required
for ubiquitin binding.
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acid sequence was produced using the catalytic core
domain of HAUSP as a template. The model was checked
manually and side-chain positions adjusted to minimize
steric clashes. The wild-type P. chabaudi UBP-1 is likely
to form a very similar structure to that found in HAUSP.
For both the V739F and V770F mutations the large size
increase of the side chain is likely to have a signiﬁcant
effect. In the HAUSP structure the valine 296 (V739F in P.
chabaudi) side-chain points into a small hydrophobic
pocket principally deﬁned by Y465 and L454. In order for
the V739F mutation to be accommodated, some move-
ment of these side chains would be needed (Fig. 7A). It is
most likely that the phenylalanine side chain would point
into a small pocket produced by V947, I887 and L633.
However, the V739F side chain comes too close to these
residues to be accommodated without further movement.
These movements are likely to affect the catalytic cys-
teine, C628, found on the same helix as L633. It is also
likely that ubiquitin binding will be affected, because Y465
interacts directly with ubiquitin.
The V770F mutation also involves a large size increase
in the side chain. The valine side-chain points into a small
hydrophobic pocket that is principally deﬁned by Y821
(UBP-1) and F4 (ubiquitin). The large increase in the size
of the V770F mutation results in dramatic protein–protein
clashes in side-chain orientations. A very small pocket is
formed by Q768, S779 (UBP-1) and E64 (ubiquitin) and is
shown in Fig. 7B. Even in this orientation the phenylala-
nine side chain comes too close to all these residues and
a large amount of protein movement would be needed to
accommodate it. It is therefore likely that the V770F muta-
tion would disrupt ubiquitin binding in this region.
Phenotypic characterization of ART-resistant
P. falciparum lines
ART-resistant parasite lines of the NF54 and 7G8 genetic
backgrounds were selected in vitro by exposing parasites
to stepwise increases in ART concentrations. Selected
drug-resistant lines were designated ART-RNF54 and ART-
R7G8. The degree of ART resistance was determined by
Fig. 5. Alignment of P. falciparum
(MAL1P1.34b) and its P. chabaudi orthologue
UBP-1. P. chabaudi AS-30CQ mutated UBP-1
and the P. falciparum homologue
MAL1P1.34b alignments are shown. The
position of the mutation V770F (and the
V739F mutation in AS-ATN) are indicated in
rectangular boxes.
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allel with their parental control lines. ART IC50 values for
ART-RNF54 and ART-R7G8 were 148 and 98 nM, respec-
tively, as compared with IC50 values of 30 and 20 nM for
control lines NF54 and 7G8 respectively. These in vitro
sensitivity assays showed that selection for resistance to
ART resulted in approximately ﬁvefold decrease in sus-
ceptibility to this drug in both resistant lines. To conﬁrm the
stability of the ART-resistant phenotype, frozen ART-RNF54
and ART-R7G8 parasite lines were thawed and after
growing in the absence of drug pressure for 2 weeks,ART
IC50 values were retested. These assays revealed ART
IC50 values of 33 nM and 25 nM for ART-RNF54 and ART-
R7G8 lines, respectively, which were comparable to their
respective parental controls. This loss of the ART resis-
tance phenotype in the drug-selected parasites indicates
Fig. 6. Alignment of P. chabaudi UBP-1 and
human HAUSP. Alignment of human HAUSP
(core protein) and P. chabaudi UBP-1.
Residues marked ‘’ are those with
presumed catalytic function, role in substrate
binding or making intramolecualar contacts
which contribute to the structure (Hu et al.,
2002). The three residues thought to be
involved in catalysis are marked ‘’. The
positions of mutations V739F and V770F are
each indicated.
♦
                  ￿   ￿￿￿ ￿   ￿ 
HAUSP     214 VGLKNQGATCYMNSLLQTLFFTNQLRKAVYM-------------------    244
              |||.|.|.|||:|||||.|:.|......:|:                    
619 VGLINLGNTCYLNSLLQALYSTVSFVVNLYIFNIDDNKELKHINNKNISN    668
HAUSP     245 -MP-----------TEGDDSSKSVPLALQRVFYELQHSDKPVGT--KKLT    280
               ||           |..::::.:..|..:|..|||:...|.:.|  ||.. 
PcUBP-1   669 EMPIKNKLSFNLNNTNMNNNNNNANLLSKRFLYELKILFKLMTTTNKKYV    718
                                ￿￿ ￿￿  ￿   ￿  ￿ 
HAUSP     281 KSFGW-----ETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFR    325
              .....     :.|::..|.||.||.|...:.:     |...:..:..:|. 
PcUBP-1   719 SPDNILGILPQELNNRNQQDVTELFRYTFEQL-----GGSEKKFLRLIFS    763
                    
                    ￿ ￿      ￿   ￿                             ￿ 
HAUSP     326 GKMVSYIQCKEVDYRSDRREDYYDIQLSI---KGKKNIFESFVD-YVAVE    371
              |.::..:||::..:.|.:.|..:|:...:   ..||...:.|.| |:..| 
PcUBP-1   764 GVVIQKVQCQKCFFISKKEEIIHDLSFHVPAKSSKKQSIQKFFDTYIQKE    813
               ￿   ￿￿￿￿           ￿                ￿￿ ￿  
HAUSP     372 QLDGDNKYDAGE-HGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIK    420
              ::.|:|||...: :..:.|.|..:.::.|..|.|.|.|:.:...:::..| 
PcUBP-1   814 KIYGNNKYKCSKCNKRRNALKWNEIISPPCHLILILNRYNWSFSSNEKKK    863
                                                 ♦
                                                 ￿    ￿  ￿￿￿    
HAUSP     421 INDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSG-DNHGGHY--VV    467
              |....:..:::.::.|          :|.|:..::||| ....|||  :. 
PcUBP-1   864 IKTHVKINKKIVVNNF----------DYRLYGGIIHSGVSASSGHYYFIG    903
                              ♦
                              ￿￿ 
HAUSP     468 YLNPKGD---GKWCKFDDDVVSRCTKE                           478
              ..:.|||   .:|.:.||..                                   
PcUBP-1   904 KKSEKGDNSKNEWYQMDDSAITKVSSK                           943
PcUBP-1
AB
Fig. 7. Structural consequences of UBP-1 mutations.
A. Residue environment around V739F. Side chains are shown as sticks with carbons coloured green for the P. chabaudi UBP-1 sequence.
The mutation to F739 in the most likely orientation is represented in stick form with carbons coloured cyan. A surface representation is shown
to indicate the tightness of ﬁt around the phenylalanine.
B. Residue environment around V770F. Side chains are shown as sticks with carbons coloured green for the P. chabaudi UBP-1 sequence
and white for ubiquitin (UbF4, UbE64). The mutation to F770 in the most likely orientation is represented in stick form with carbons coloured
cyan. A surface representation is shown to indicate the tightness of ﬁt around the phenylalanine.
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transient drug-induced ART resistance phenotype.
Sequence analysis of the pfcrt, pfmdr1 and pfubp-1
genes
To study the molecular basis of (transient) ART resis-
tance, we polymerase chain reaction (PCR)-ampliﬁed and
sequenced the pfcrt, pfmdr1 and pfubp-1 genes of ART-
resistant and wild-type parasite lines. We selected these
genetic determinants based on the observation that muta-
tions in these genes modulate susceptibility to ART and
other antimalarials. There were no sequence changes
observed at the polymorphic positions of the pfcrt (posi-
tion 76) and pfmdr1 (positions 86, 1034, 1042 and 1246)
genes of ART-RNF54 and ART-R7G8 lines grown in the pres-
ence of drug. Sequencing of the complete open reading
frame of the pfubp-1 gene of ART-resistant lines also did
not reveal any sequence change compared with the
parental lines, although two novel SNPs were detected in
the 7G8 line at V260A and E265K. These investigations
suggest that the transient resistance phenotye of theART-
RNF54 andART-R7G8 lines was due to reversible modulation
of gene expression.
Discussion
We have used LGS to analyse the uncloned progeny of a
genetic cross between the artemisinin- (and artesunate-)
resistant clone, AS-ART and the sensitive clone AJ,
before and after treatment with artemisinin, using AFLP
marker intensities and genome-wide pyrosequencing.
Using the pooled uncloned progeny from three indepen-
dent genetic crosses, we obtained a selection valley on
chromosome 2, and also evidence of selection on chro-
mosomes 1, 8 and 14. An analysis of the three individual
component genetic crosses by pyrosequencing (supple-
mentary data) for loci on chromosomes 2, 6 (control), 8
and 14 conﬁrms possible selection signatures on chromo-
some 2, 8 and 14. The similarity of our quantitative AFLP
and pyrosequencing data conﬁrms that genome-wide
pyrosequencing is a useful tool for the de novo mapping
of genes underlying selectable phenotypes in LGS-type
experiments, as previously suggested (Cheesman et al.,
2007).
Because pcatp6 (encoding SERCA Ca2+-ATPase) is
located within chromosome 2 (Fig. 3) and because its
involvement in artemisinin activation and resistance has
been proposed (Jambou et al., 2005; Uhlemann et al.,
2005), we wished to investigate whether there were
pcatp6 mutations which might affect the activity or expres-
sion of this protein. However, there were no mutations in
AS-ART coding region, over 4 kb of 5′-UT or over 1 kb of
3′-UT (Afonso et al., 2006).
Instead, within P. chabaudi chromosome 2, we identi-
ﬁed two mutations in a gene encoding a DUB enzyme
(UBP-1); V739F in the artesunate-resistant clone AS-ATN
(relative to its progenitor AS-15CQ), and V770F in the
high chloroquine-resistant clone AS-30CQ (relative to
AS-15CQ). These two mutations within the same gene
occurred independently in two different lines under selec-
tion with artesunate and chloroquine respectively. Each
mutation produces an identical substitution (V to F), and
occurs in one of only two regions that are highly con-
served relative to the orthologous P. falciparum gene.
An analysis of the structure of a human homologue
(HAUSP) of the mutated P. chabaudi protein, showed that
residues underlying structural, intermolecular or catalytic
roles in HAUSP are highly conserved in the P. chabaudi
DUB. Both mutations increase the size of the side group
and map onto residues that are likely to be critical to the
molecule’s activity.
Importantly, while it is theoretically possible to argue
that V739F could confer artesunate/artemisinin resistance
relative to AS-15CQ, there is no corresponding mutation
to explain the resistance of AS-ART relative to AS-30CQ,
because mutation V770F is present in both AS-ART and
AS-30CQ.
Some reports have linked protein ubiquitination/
deubiquitination to DNA repair function (Huang and
D’Andrea, 2006). However, we reject the hypothesis that
the mutations reported here may underlie a change in a
phenotype known as Accelerated Resistance to Multiple
Drugs, alternatively known as a ‘mutator’ phenotype
(Rathod et al., 1997). Such mutations may occur during
the original selection of drug-resistant mutants (i.e. at
some stage during the generation of the drug-resistantAS
lineage). However, these pre-existing mutations would not
be selected during LGS experiments unless, of course,
they are genetically linked to other, as yet, unidentiﬁed,
mutations that underlie the resistance phenotype.
We have considered other possible interpretations. The
ﬁrst is simply that there is a mutation in a different gene
(gene X) on chromosome 2 that arose during artemisinin
selection on AS-30CQ during the AS-ART mutant
generation. This mutation could be responsible for the
selection valley obtained during LGS, and would differen-
tiate AS-ART and AS-30CQ. Whether or not AS-ATN also
has a mutation in the same (or similar) gene X relative to
AS-15CQ is an open question that can be addressed by
analysing a genetic cross betweenAS-ATN andAJ and by
comparative sequencing of AS-ATN. We are currently
investigating the presence of other mutations in this
linkage group by further comparative sequencing of chro-
mosome 2 genes from the resistant clones and their sen-
sitive progenitors. If gene X is mutated in both AS-ATN
and AS-ART, and if this mutation is causing the selection
of chromosome 2 in LGS, what would be our interpreta-
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is that UBP mutations, which are all relative to the parasite
AS-15CQ, may compensate for mutations selected during
the acquisition of intermediate resistance to CQ in
AS-15CQ fromAS-3CQ (resistant to low concentrations of
chloroquine) (Fig. 1). This would suggest that a mutation
in AS-15CQ has compromised the parasite’s normal
physiological ﬁtness and that subsequent selections with
other drugs have selected a compensatory UBP mutation
that abrogates the ﬁtness costs of the AS-15CQ mutation.
If, on the other hand, gene X lies on a different chro-
mosome (for example, chromosomes 1, 8 and 14), we
must consider why chromosome 2 shows a selection
valley. We would suggest that the compensation of muta-
tions underlying intermediate chloroquine resistance in
AS-15CQ by mutations in UBP-1 is required for the
expression of resistance to artemisinin, i.e. that the phe-
notypic expression of a mutation in gene X is epistatic to
the UBP mutations.
We wish to emphasize one possible implication of this
interpretation. The UBP-1 mutations that may fulﬁl this
role occurred during artesunate selection of AS-ATN and
during chloroquine selection of AS-30CQ. The fact that
similar mutations in the same gene were selected during
long-term passage in the presence of two different drugs
suggests that there may be some underlying common
cellular function that might be compromised during treat-
ment with artemisinin derivatives or chloroquine, such as
regulation of oxidative stress in drug-treated parasites
(Krungkrai and Yuthavong, 1987; Tilley et al., 2001;
Becker et al., 2004). Indeed a DUB enzyme was a primary
target of oxidative stress in mutant superoxide
dismutase-1 (SOD1) transgenic mice (Poon et al., 2005).
Also, the expression of its homologue was modiﬁed by
oxygen stress in a human tumour cell line; upregulation
and downregulation were associated with surviving and
apoptotic cells, respectively (Shen et al., 2006).
We also wish to suggest that the basis of artemisinin
resistance is likely to be multigenic for the following
reasons. Artemisinin resistance in P. chabaudi required
signiﬁcant passage using subcurative doses of artemisi-
nin, and required the use of parasites with previously
generated chloroquine resistance. Stable, artemisinin
resistance is difficult to obtain with P. falciparum in culture.
Selection of genetic crosses with artemisinin is suggest-
ing an important contribution of a gene on chromosome 2,
and perhaps, to a lesser extent, an involvement of other
genes on, for example, chromosomes 1, 8 and 14.
We have also selected two lines of P. falciparum para-
sites that show decreased susceptibility to artemisinin but
whose phenotype is not stable. These lines do not bear
mutations in pfubp-1. In contrast, the P. chabaudi para-
sites AS-ART and AS-ATN are both genetically stable and
selected in vivo. These factors emphasize the value of the
P. chabaudi rodent malaria for the generation and genetic
characterization of mutations underlying drug resistance.
We await with interest a characterization of DUB enzymes
in genetically stable artemisinin-resistant P. falciparum
mutants.
What effect might UBP-1 mutations have on malarial
parasites? We cautiously expect that a partial loss of
UBP-1 activity might lead to an increase in degradation
(via the proteasome) of proteins that act as UBP-1
substrates. Identiﬁcation of UBP-1 substrates and UBP-1
allelic exchange transfections of P. falciparum parasites in
culture should allow us to address these questions, and
are planned. Transfection of mutated ubp-1 genes in
P. chabaudi would allow us to evaluate their role in an in
vivo system. Up to now, however, successful stable trans-
fection is not an established technique.
Previous studies have considered the ubiquitination/
deubiquitination of mdr1 in human cancer cell lines and its
effects upon intracellular drug accumulation and
responses to drugs. For example Zhang et al. (2004)
report that in a human breast cancer cell line, the mdr1
gene product, P-glycoprotein (P-gp), is constitutively ubiq-
uitinated and that increased ubiquitination enhanced the
rate of degradation of the mdr1 gene product. Enhanced
ubiquitination increased drug accumulation and sensitivity
to the drugs doxorubicin and vinblastine, both of which are
normally modulated by mdr1 expression. Because the
P. falciparum homologue, pfmdr1, has been shown to
modulate the responses of malaria parasites to both arte-
misinin derivatives and to chloroquine, the effect of UBP-1
mutations upon possible post-translational modiﬁcations
(e.g. ubiquitination or phosphorylation) of the mdr1 gene
product may be worthy of further study in P. falciparum.
We acknowledge that we have yet to provide direct
evidence of a role for mutations in UBP-1 in artemisinin
resistance in the rodent malaria parasite P. chabaudi.
Nevertheless, we believe that the data presented here are
important for two main reasons. First, they suggest new
opportunities for genetic and biochemical investigations
into drug resistance in malaria, especially in the vital area
of resistance to artemisinin based therapies. Second, we
believe that the demonstration of mutations in UBP and its
deep involvement in central cellular processes such as
responses to oxidative damage may encourage concep-
tual developments in our understanding of drug resis-
tance, its genetic basis and its evolution.
Experimental procedures
Mice, parasites (cloned isolates, drug-resistant mutants),
mosquitoes
Four- to six-week-old female CBA-inbred mice were used for
all parasite infections. They had permanent access to 41B
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supplemented with 0.05% p-amino-benzoic acid (pABA).
The Plasmodium chabaudi chabaudi (referred to here as
P. chabaudi) parasites investigated here (Fig. 1) include the
drug-resistant parasites AS-15CQ, AS-30CQ (Padua, 1981),
AS-ART andAS-ATN (Afonso et al., 2006), which are derived
from the drug-sensitive cloned isolate AS obtained from
thicket rats, Thamnomys rutilans, in the Central African
Republic (Landau, 1965; Landau and Chabaud, 1965). AJ is
a genetically different drug-sensitive cloned isolate. All para-
site clones were available as cryopreserved stabilates, deep-
frozen in liquid nitrogen.
Anopheles stephensi mosquitoes were maintained in a
dedicated insectary as previously described (Martinelli et al.,
2005a).
In vitro selection of artemisinin-resistant parasite lines
and antimalarial drug assays
Plasmodium falciparum NF54 (chloroquine-sensitive) and
7G8 (chloroquine-resistant) strains were used for the selec-
tion of artemisinin (ART) resistance. Drug resistance selec-
tion experiments were started with approximately 5 ¥ 10
10
mixed stage parasites, which were exposed to 10 nM of ART
for 10 days. Cultures were maintained carefully by feeding
two to three times daily with ART-containing complete media.
Cultures were smeared every 2–3 days and healthy asexual
stage parasites were observed by examining Giemsa-stained
thin blood smears. After initial drug exposure, ART drug con-
centration was increased to 25 nM for both parasite lines and
kept at this level for the following 12 days. At this drug con-
centration dying asexual- and gametocyte-stage parasites
were observed by microscopic examination of Giemsa-
stained smears. The ART drug selection level was then
increased to 50 nM that apparently eliminated asexual stage
parasites, and cultures were further maintained at this drug
level for following 4 weeks. During the entire selection
process 30–40% red blood cells were replaced with freshly
washed cells once a week. For both parasite lines, ring stage
parasites growing in the presence of ART at 50 nM concen-
tration were observed by day 45. Once the parasitaemias
reached 2–3%, frozen stocks ofART-selected parasites were
prepared using Glycerolyte 81. Parasites were phenotypically
characterized for their ART response proﬁles using
[
3H]-hypoxanthine incorporation assays as described previ-
ously (Desjardins et al., 1979).
Genetic cross
For each genetic cross, six mosquito cages (approximately
20 cm cubes) were set up each containing approximately 200
female A. stephensi mosquitoes, 5–7 days old. Glucose was
removed from cages 24 h before mosquito feeds. Four mice
were inoculated with both AJ and AS-ART (1 ¥ 10
6 parasites
of each) and two mice were inoculated with either one of the
parental clones. All mice were monitored for the presence of
gametocytes. On day 6 post infection, mice with mixed infec-
tions or single infections of the parental parasites were each
laid on top of a mosquito cage for 30 min. Glucose and water
solution were then replaced and non-blood fed mosquitoes
removed. After 7–9 days, 10 mosquitoes from each cage
were removed and their midguts examined for the presence
of oocysts. After 14 days following feeding, the salivary
glands were removed from the mosquitoes and placed in
50% Ringer’s solution and 50% heat-inactivated calf serum.
The glands were gently disrupted using a pestle and mortar
to release the sporozoites. This suspension was kept on ice,
and injected intraperitoneally into a group of mice in 0.1 ml
aliquots.
Drugs and selection of cross-progeny (LGS)
When the sporozoite-induced infections (‘unpassaged’)
reached parasitaemias of between 10% and 15%, the para-
sites were harvested, pooled and inoculated (1 ¥ 10
7 para-
sites) into two groups of mice, one treated with artemisinin
(‘treated’) and the other left untreated (‘untreated’). Artemisi-
nin was dissolved in dimethylsulphoxide and administered
orally at a dose of 25 mg kg
-1 of mouse body weight daily at
24 h intervals for 5 days, starting 3 h after parasite challenge.
The treated and the untreated blood-stage cross progeny
were allowed to grow until parasitaemias reached 30%-40%
for untreated, and 15%-20% for treated, when parasites
were harvested (days 6 and 12 pi respectively).
Parasite harvesting
Mouse lymphocytes and other nucleated cells were removed
from blood by ﬁltration (twice) through 5 ml columns of pow-
dered cellulose (CF11, Sigma) washed with citrate saline.
Blood was then further ﬁltered through Plasmodipur™ ﬁlters
(Euro-Diagnostica) twice. The ﬁltrate was centrifuged for
5 min at 3000 r.p.m. and the supernatant removed, leaving a
pellet of packed cells. The pellet was resuspended in two
volumes of 0.15% saponin in phosphate-buffered saline
(PBS). After lysis of erythrocytes, PBS was added in excess
to prevent parasite lysis. This solution was then centrifuged at
4000 r.p.m. for 5 min and washed twice in PBS. Supernatant
was discarded and pellets stored at -70°C.
DNA extraction, AFLP ampliﬁcation, analysis and
nomenclature
DNA from ‘unpassaged’ ‘treated’ and ‘untreated’ groups was
extracted, prepared for AFLP analysis, and ampliﬁed using
‘non-selective’ and ‘selective’ oligonucleotide primers, as pre-
viously described (Grech et al., 2002). Polymorphic markers
(between AS-ART and AJ) were named to denote speciﬁcity
of the polymorphic band, the size of the band (relative to
other polymorphic bands in the same gel lane) and the selec-
tive bases used. Thus, AJAG02CT denotes the second
largest AJ-speciﬁc band obtained using EcoRI primers with
AG as additional ‘selective’ 3′-nucleotides, and CT as ‘selec-
tive’ nucleotides on the MseI primers. Genomic DNA from
P. falciparum drug-selected and parental lines was prepared
using DNeasy Blood and Tissue Kit (Qiagen).
Determination of CIs of AJ-speciﬁc bands
Marker band intensities were measured with PhosphorIm-
ager and IMAGEQUANT software (Molecular Dynamics), and
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estimate the intensity of a polymorphic marker in a mixture,
relative to its intensity in the parental clone (Martinelli et al.,
2004). CIs of polymorphic markers are deﬁned as the RII of
an AFLP marker in the cross progeny selected in ‘treated’
mice (RIIt), divided by the RII of the marker of the cross
progeny grown in a parallel ‘untreated’ group of mice (RIIut),
and expressed as a percentage, i.e. CI = (RIIt/RIIut) ¥ 100.
Mapping of AFLP markers
Markers with low CIs were identiﬁed and their position on the
genetic linkage map (Martinelli et al., 2005b) noted. AFLP
bands that appeared to be under selection were sequenced
as previously described (Hunt et al., 2004b). The positions of
corresponding sequences in the P. falciparum genome were
determined as previously described (Hunt et al., 2004b).
Brieﬂy, P. chabaudi contig sequences containing highly
similar AFLP sequences were identiﬁed by BLAST search.
These contigs (usually containing a number of genes) were
used to identify loci in P. falciparum containing orthologous
genes, by BLAST search. These loci were expressed in the
form pfxx-yyyy, where xx denotes the P. falciparum chromo-
some and where yyyy denotes the position in kb. The
corresponding loci in P. chabaudi were predicted using a
genome-wide syntenic map (Kooij et al., 2006).
Sequencing, sequence analysis and SNP identiﬁcation
Polymerase chain reactions were sequenced using the ABI
PRISM Big DyeTM Terminator Cycle Sequencing Ready
Reaction Kit (PE Applied Biosystems) according to manufac-
turer’s instructions. Sequencing reaction products were puri-
ﬁed by precipitation with sodium acetate and 95% ethanol,
and washed in 70% ethanol, before analysis on an ABI 3700
sequencer. All fragments were sequenced in both forward
and reverse directions. Sequencing results were analysed
using SeqED v1.0.3 software (Applied Biosystems, 1992)
and CHROMAS 2.31 (Technelysium Pty). To determine the
sequence at the pfcrt polymorphic position 76, a 600 bp frag-
ment was ampliﬁed by using the primers CF5C and BB84.
The 5′ region of the pfmdr1 gene encompassing the polymor-
phic site 86 was ampliﬁed as a 1.0 kb fragment using primers
P285 and P423. For sequencing of the pfmdr1 polymorphic
positions 1034, 1042 and 1246, a 2.0 kb fragment was PCR-
ampliﬁed with primers P213 and P215. The full-length 4.0 kb
PfUBP-1 gene was PCR-ampliﬁed with primers P1595 and
P1597 and fully sequenced on both strands using internal
primers.
Oligonucleotide primers
Oligonucleotide primers used for ampliﬁcation and sequenc-
ing of candidate genes, and for pyrosequencing analysis are
detailed in Supplementary material.
Pyrosequencing
Assays to estimate proportions of SNPs were designed using
Assay design software v1.0.6 (Biotage AB, Sweden). This
deﬁnes two oligonucleotides as PCR primers, one of which is
biotinylated, and a sequencing primer close to the SNP. The
primers used for each of the assays are given in Supplemen-
tary material. Pyrosequencing assays were performed on a
Biotage Pyrosequencer HS96A, according to manufacturer’s
procedures.
Identiﬁcation of DUB structural homologue and
structural analysis
The sequence for P. chabaudi was entered into Phyre
(Protein Homology/analogy Recognition Engine) software,
which identiﬁed the catalytic core domain of HAUSP as a
template (pdb id 1NBF) and created an initial protein model.
The program Coot (Emsley and Cowtan, 2004) was used to
manually examine the resultant model and adjust side chains
to minimize steric clashes. The modelled mutations were
created using Coot and also manually adjusted to minimize
steric clashes. The structural ﬁgures were created using the
program PyMOL (Delano, 2002).
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